PTAB puts a stop to Allergan's tribal sovereign immunity gamble from ipkitten.blogspot.com Substance over form matters in RESTASIS IPR disputeBack in September 2017, the AmeriKat posted about the transactional strategy executed by Allergan and the Saint Regis Mohawk Tribe to avoid the jurisdiction of the PTAB ...
Share via E–mail | Twitter | Facebook
L'Oreal v RN Ventures - The Registered Design Perspective from ipkitten.blogspot.com The '747 Design (plainly not a plane)
L'Oréal Société Anonyme RN Ventures Ltd (Rev 1) [2018] EWHC 173, the recent
decision by Mr Justice Carr, has been given the Amerikat treatment
here and
here ... Share via E–mail | Twitter | Facebook
On Sale and Public Use Bars Webinar from www.patentdocs.org Strafford will be offering a webinar entitled "On Sale and Public Use Bars to Patentability: Minimizing the Risk of Patent Ineligibility or Invalidation" on March 15, 2018 from 1:00 to 2:30 pm (EDT ...
Share via E–mail | Twitter | Facebook
IPLAC Presentation on EPO from www.patentdocs.org The Intellectual Property Law Association of Chicago (IPLAC) Patents-International Committee will be offering a presentation by Alfred Keyack, EPO Attaché to the United States, entitled "Inside the European Patent Office: Questions & Answers" on March 7 ...
Share via E–mail | Twitter | Facebook
USPTO 2018 Business Methods Partnership Meeting from www.patentdocs.org The U.S. Patent and Trademark Office will be holding 2018 Business Methods Partnership Meeting (BMPM) from 1:00 to 4:00 pm (ET) on March 15, 2018. The BMPM was established to create a ...
Share via E–mail | Twitter | Facebook
MBHB Webinar on PTAB from www.patentdocs.org McDonnell Boehnen Hulbert & Berghoff LLP will be offering a live webinar entitled "Top Stories at the PTAB: What You Need to Know" on March 13, 2018 from 10:00 am to 11:15 am (CT ...
Share via E–mail | Twitter | Facebook
Swiss Panel Looks At Value-Based Drug Pricing, Link Between R&D And Prices from www.ip-watch.org Some products are too cheap, generic drug companies do not invest in them because they do not make enough money out of them. Others seem astronomically expensive, and are said to include the costs of ...
Share via E–mail | Twitter | Facebook